Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02945670 · ClinicalTrials.gov registry record
Using Focus Group to Explore Cultural Acceptability of Contraception
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 64
- Enrollment target
NCT02945670: Completed study, sponsored by University of Pittsburgh.
NCT02945670 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02945670 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to learn what women of childbearing age think of Long Acting Reversible Contraception. A variety of myths regarding LARCs have been described in the literature. This study is designed to asses women's cultural belief's regarding LARCs. Investigators are looking to collect information from women in general, rather than solely who are seeking contraception. Investigators will be recruiting women ages 18-45 years from seven family health centers affiliated with UPMC. Participants will be asked to a attend a 60-90 minutes focus group session. During the session the facilitator will try to engage participants in a discussion about contraception in general. They will also be asked to complete a short demographic survey of 8-12 questions. Data from focus groups will be assessed for recurring themes which will be used to create a cultural survey instrument that will be used in the second phase of the study.
Primary Outcome
Level of acceptance: 1-Totally not accepted 2-May accept 3-Neither accept/not accept 4-Accept with preservation 5-Totally accept
Interventions
- BEHAVIORAL Focus Group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2017-01-02 |
| Est. Completion | 2017-03-30 |
What the finished NCT02945670 record still lists
NCT02945670 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Focus Group is the first listed.
NCT02945670 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02945670 about?
NCT02945670 is a clinical study titled "Using Focus Group to Explore Cultural Acceptability of Contraception". The purpose of this study is to learn what women of childbearing age think of Long Acting Reversible Contraception. A variety of myths regarding LARCs have been described in the literature. This study is designed to asses women's cultural belief's regarding LARCs. Investigators are looking to collec...
What is the current status of trial NCT02945670?
This trial is currently completed. The enrollment target is 64 participants. The study started on 2017-01-02. Estimated completion is 2017-03-30.
What interventions are being tested in trial NCT02945670?
The interventions under investigation include: Focus Group (BEHAVIORAL).
Who is sponsoring clinical trial NCT02945670?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI